17-Nov-2026 23:18:44

CIPLAGeneral news

CIPLA : USFDA CLASSIFIES INVAGEN FACILITY INSPECTION AS NO ACTION INDICATED

• USFDA classified the inspection at InvaGen's Hauppauge, Long Island, New York manufacturing facility as No Action Indicated (NAI) • Inspection was conducted from 19 October 2026 to 22 October 2026 • InvaGen Pharmaceuticals Inc. is a wholly owned subsidiary of Cipla • NAI classification communicated by USFDA vide its communication dated 17 November 2026

Cipla Limited

Open attachment

← Back to feed